What's new in pharmaOctober 3, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior WriterNot yet a STAT+ subscriber? Now's your chance, with a flash sale. Alex Hogan/ STAT STAT+ | Colorado board makes first-in-the-nation move by setting a payment limit on an Amgen drug The landmark vote may encourage other states to pursue similar strategies to contain spending on prescription medicines. By Ed Silverman STAT+ | Trump administration delays effort to address Medicare drug price negotiation loophole While Trump presses pharma companies to lower their prices, he rarely mentions that Medicare already negotiates drug prices, thanks to Biden. By John Wilkerson She's leading NIH's push to reduce the use of animals in biomedical research Kleinstreuer is creating a NIH office devoted to animal testing alternatives, the Office of Research, Innovation, Validation, and Application (ORIVA). By Sara Talpos Jose Luis Magana/AP FDA approves another generic abortion pill, prompting outrage from conservatives The regulatory formality quickly triggered pushback from anti-abortion groups and politicians aligned with the Trump administration. By Associated Press STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments